233 related articles for article (PubMed ID: 34801997)
21. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
22. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation.
Lee ES; Shen Q; Pitts RL; Guo M; Wu MH; Sun SC; Yuan SY
J Vasc Surg; 2011 Aug; 54(2):454-9; discussion 459-60. PubMed ID: 21620625
[TBL] [Abstract][Full Text] [Related]
23. Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis.
Bieniaś B; Sikora P
Dis Markers; 2020; 2020():9520309. PubMed ID: 32670438
[TBL] [Abstract][Full Text] [Related]
24. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
25. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
[TBL] [Abstract][Full Text] [Related]
26. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
[TBL] [Abstract][Full Text] [Related]
28. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.
Gluba-Brzózka A; Michalska-Kasiczak M; Franczyk B; Nocuń M; Toth P; Banach M; Rysz J
Lipids Health Dis; 2016 Feb; 15():22. PubMed ID: 26843213
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
30. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
31. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
32. The effect of surgery on the levels of matrix metalloproteinases in patients with inguinal hernia.
Strohalmová S; Levová K; Kuběna AA; Krška Z; Hoskovec D; Zima T; Kalousová M
Physiol Res; 2021 Aug; 70(4):627-634. PubMed ID: 34062071
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders.
Hurnaus S; Mueller-Felber W; Pongratz D; Schoser BG
Eur Neurol; 2006; 55(4):204-8. PubMed ID: 16772717
[TBL] [Abstract][Full Text] [Related]
34. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.
Beaudeux JL; Giral P; Bruckert E; Bernard M; Foglietti MJ; Chapman MJ
Atherosclerosis; 2003 Jul; 169(1):139-46. PubMed ID: 12860260
[TBL] [Abstract][Full Text] [Related]
35. Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.
Nissi R; Talvensaari-Mattila A; Kotila V; Niinimäki M; Järvelä I; Turpeenniemi-Hujanen T
Reprod Biol Endocrinol; 2013 Jan; 11():2. PubMed ID: 23320481
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.
Sekiuchi M; Kudo A; Nakabayashi K; Kanai-Azuma M; Akimoto Y; Kawakami H; Yamada A
Clin Exp Nephrol; 2012 Dec; 16(6):863-74. PubMed ID: 22614167
[TBL] [Abstract][Full Text] [Related]
37. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
38. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
39. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
[TBL] [Abstract][Full Text] [Related]
40. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
